NewLink Genetics Corp. Sets New 1-Year High at $37.42 (NLNK)
NewLink Genetics Corp. (NASDAQ:NLNK) set a new 52-week high during trading hours on Thursday, American Banking & Market News reports. The company traded as high as $37.42 and last traded at $37.39, with a volume of 581,327 shares. The stock had previously closed at $35.25.
NLNK has been the subject of a number of recent research reports. Analysts at Stifel Nicolaus raised their price target on shares of NewLink Genetics Corp. from $31.00 to $53.00 in a research note to investors on Wednesday, January 22nd. They now have a “buy” rating on the stock. They noted that the move was a valuation call. Five analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average price target of $31.20.
NewLink Genetics Corp. has a 52 week low of $11.19 and a 52 week high of $36.81. The stock’s 50-day moving average is $26.04 and its 200-day moving average is $20.14. The company’s market cap is $945.2 million.
NewLink Genetics Corp. (NASDAQ:NLNK) last released its earnings data on Monday, November 11th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.01. During the same quarter in the previous year, the company posted ($0.28) earnings per share. On average, analysts predict that NewLink Genetics Corp. will post $-1.29 earnings per share for the current fiscal year.
NewLink Genetics Corporation operates as a biopharmaceutical company. The Company, based in the United States, is focused on discovering, developing, and commercializing immunotherapeutic products to improve cancer treatment options for patients and physicians.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.